Karizoo
Thyroxanil 600 microgram for cats and dogs 100 tablets

Treatment of primary and secondary hypothyroidism in cats and dogs

Some countries require a prescription to be issued for the sale of this drug.

Thyroxanil 600 microgram is a white, round and convex tablet with a cross-shaped break line on one side and the number 600 on the other side, for the treatment of primary and secondary hypothyroidism in cats and dogs.

One tablet of Thyroxanil 600 microgram contains:

Active substance:

  • Levothyroxine sodium 600 μg (equivalent to levothyroxine 583 μg)

Excipients:

  • Magnesium oxide, heavy
  • Cellulose, microcrystalline
  • Sodium starch glycolate (type A)
  • Magnesium stearate

Thyroxanil 600 microgram:

  • Must not be used in dogs and cats suffering from uncorrected adrenal insufficiency.
  • Must not be used in cases of known hypersensitivity to levothyroxine sodium or to any of the excipients.

Thyroxanil 600 microgram posology:

  • For oral administration.
  • The recommended starting dose for dogs and cats is 20 μg levothyroxine sodium per kg body weight per day given as a single daily dose or in two equally divided doses.
  • Because of variability in absorption and metabolism, the dosage may require alterations before a complete clinical response is observed. The initial dosage and frequency of administration are merely a starting point. Therapy has to be highly individualised and tailored to the requirements of the individual animal especially for cats and small dogs.
  • The dose should be adjusted based on clinical response and plasma thyroxine levels. In the dog and cat, absorption of levothyroxine sodium may be affected by the presence of food. The timing of treatment and its relation to feeding should therefore be kept consistent from day to day. To adequately monitor therapy, trough values (just prior to treatment) and peak values (about four hours after dosing) of plasma T4 can be measured. In adequately dosed animals peak plasma concentration of T4 should be in the high-normal range (approximately 30 to 47 nmol/l) and trough values should be above approximately 19 nmol/l. If T4 levels are outside this range the levothyroxine sodium dose can be adjusted in appropriate increments until the patient is clinically euthyroid and serum T4 is within the reference range.
  • The 200 μg tablets enable adjustment of the levothyroxine dose by 50 μg increments per animal and 600 μg tablets enable adjustment of the levothyroxine dose by 150 μg increments per animal. Plasma T4 levels can be retested two weeks after change of dosage, but clinical improvement is an equally important factor in determining individual dosage and this will take four to eight weeks. When the optimum replacement dose has been attained, clinical and biochemical monitoring may be performed every 6 – 12 months.

Thyroxanil 600 microgram is a white, round and convex tablet with a cross-shaped break line on one side and the number 600 on the other side, for the treatment of primary and secondary hypothyroidism in cats and dogs.

One tablet of Thyroxanil 600 microgram contains:

Active substance:

  • Levothyroxine sodium 600 μg (equivalent to levothyroxine 583 μg)

Excipients:

  • Magnesium oxide, heavy
  • Cellulose, microcrystalline
  • Sodium starch glycolate (type A)
  • Magnesium stearate

Thyroxanil 600 microgram:

  • Must not be used in dogs and cats suffering from uncorrected adrenal insufficiency.
  • Must not be used in cases of known hypersensitivity to levothyroxine sodium or to any of the excipients.

Thyroxanil 600 microgram posology:

  • For oral administration.
  • The recommended starting dose for dogs and cats is 20 μg levothyroxine sodium per kg body weight per day given as a single daily dose or in two equally divided doses.
  • Because of variability in absorption and metabolism, the dosage may require alterations before a complete clinical response is observed. The initial dosage and frequency of administration are merely a starting point. Therapy has to be highly individualised and tailored to the requirements of the individual animal especially for cats and small dogs.
  • The dose should be adjusted based on clinical response and plasma thyroxine levels. In the dog and cat, absorption of levothyroxine sodium may be affected by the presence of food. The timing of treatment and its relation to feeding should therefore be kept consistent from day to day. To adequately monitor therapy, trough values (just prior to treatment) and peak values (about four hours after dosing) of plasma T4 can be measured. In adequately dosed animals peak plasma concentration of T4 should be in the high-normal range (approximately 30 to 47 nmol/l) and trough values should be above approximately 19 nmol/l. If T4 levels are outside this range the levothyroxine sodium dose can be adjusted in appropriate increments until the patient is clinically euthyroid and serum T4 is within the reference range.
  • The 200 μg tablets enable adjustment of the levothyroxine dose by 50 μg increments per animal and 600 μg tablets enable adjustment of the levothyroxine dose by 150 μg increments per animal. Plasma T4 levels can be retested two weeks after change of dosage, but clinical improvement is an equally important factor in determining individual dosage and this will take four to eight weeks. When the optimum replacement dose has been attained, clinical and biochemical monitoring may be performed every 6 – 12 months.
28.90
Order within 6h 35m 46s (before 12AM)
And receive your order
on Monday 23 October
AIR FREIGHT